Option chain shows key data for PolyPid's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for PolyPid.

PolyPid (NASDAQ:PYPD) Stock, Option Chain

PolyPid

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

Analysts

News

Price Target

Markets

Analyst Ratings

Trading Ideas

ACVA

AVXL

KMPR

PYPD

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

movers image

Intraday Update

Movers

BMRC

CERO

CGTX

COMM

COUR

CPTN

CTRI

IART

ITRG

LGVN

LIPO

LUXH

MESO

NIPG

NISN

NLSP

NOVA

NUWE

OPTT

PGHL

PHIO

RNLX

SERV

TIVC

TNDM

TSLA

TWOU

VERO

VTVT

VTYX

YIBO

Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Penny Stocks

Small Cap

AIMD

ALLO

ANGO

APLT

ATXI

AXGN

BNZI

CISO

CPRX

CYCC

DRMA

ELAN

EXAI

IMCR

Intelligent Bio Solutions Inc. - Common Stock

INBS

KORE

KRUS

LSDI

NEXI

OMGA

PNST

PTON

RCAC

SABS

SMFL

SWVL

TBPH

VERB

VYGR

Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

PolyPid Ltd

Press Releases

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Health Care

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

General

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Earnings

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

PolyPid to Participate in the 37th Annual ROTH Conference

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid to Participate in The Citizens Life Sciences Conference

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

Comments

PolyPid

PolyPid (PYPD) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell